1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow MSI: new trials by email Literature Review of MSI trials Research Report on MSI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Atezolizumab, Bevacizumab - MSI, ColoRectal Cancer | Phase 2 | Terminated | Vall d'Hebron Institute of Oncology | 46 | 2017-11-24 | 2025-10-01 |
Activated Protein C Resistance (1) · Colorectal Neoplasms (1)
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Colonic Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1)
Bevacizumab (1) · atezolizumab (1)
Vall d'Hebron Institute of Oncology (1)
Belgium (1) · Italy (1) · Netherlands (1) · Spain (1)
Josep Tabernero Caturla, Prof (1)
2016 (1)